# Duos Technologies Group, Inc.: financial statements, quarterly

DUOT · Nasdaq · CIK 1396536 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/duot.md) · [Financials](/companies/duot/financials.md) · [Filings](/companies/duot/filings.md) · [Insiders](/companies/duot/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/duot/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.5](/filings/0001079973-24-001587.md) | [1.5 d](/filings/0001079973-25-000555.md) | [1.1](/filings/0001553350-25-000046.md) | [1.5](/filings/0001079973-25-001297.md) | [3.2](/filings/0001079973-25-001713.md) | [1.5 d](/filings/0001079973-26-000405.md) | [5.0](/filings/0001553350-26-000088.md) | [4.8](/filings/0001079973-26-001151.md) | [6.9](/filings/0001079973-25-001713.md) | [9.5 d](/filings/0001079973-26-000405.md) | [2.7](/filings/0001553350-26-000088.md) | [6.2](/filings/0001079973-26-001151.md) |
| Cost of revenue | $m | [1.3](/filings/0001079973-24-001587.md) | [1.2 d](/filings/0001079973-25-000555.md) | [1.0](/filings/0001553350-25-000046.md) | [1.7](/filings/0001079973-25-001297.md) | [2.3](/filings/0001079973-25-001713.md) | [1.8 d](/filings/0001079973-26-000405.md) | [3.6](/filings/0001553350-26-000088.md) | [3.0](/filings/0001079973-26-001151.md) | [4.4](/filings/0001079973-25-001713.md) | [6.9 d](/filings/0001079973-26-000405.md) | [1.1](/filings/0001553350-26-000088.md) | [2.7](/filings/0001079973-26-001151.md) |
| Gross profit | $m | [0.2](/filings/0001079973-24-001587.md) | [0.3 d](/filings/0001079973-25-000555.md) | [0.1](/filings/0001553350-25-000046.md) | [(0.2)](/filings/0001079973-25-001297.md) | [0.9](/filings/0001079973-25-001713.md) | [(0.3) d](/filings/0001079973-26-000405.md) | [1.3](/filings/0001553350-26-000088.md) | [1.8](/filings/0001079973-26-001151.md) | [2.5](/filings/0001079973-25-001713.md) | [2.5 d](/filings/0001079973-26-000405.md) | [1.6](/filings/0001553350-26-000088.md) | [3.4](/filings/0001079973-26-001151.md) |
| Research and development | $m | [0.5](/filings/0001079973-24-001587.md) | [0.4 d](/filings/0001079973-25-000555.md) | [0.4](/filings/0001553350-25-000046.md) | [0.4](/filings/0001079973-25-001297.md) | [0.4](/filings/0001079973-25-001713.md) | [0.4 d](/filings/0001079973-26-000405.md) | [0.4](/filings/0001553350-26-000088.md) | [0.3](/filings/0001079973-25-001297.md) | [0.1](/filings/0001079973-25-001713.md) | [0.0 d](/filings/0001079973-26-000405.md) | not reported | not reported |
| Operating income | $m | [(3.0)](/filings/0001079973-24-001587.md) | [(3.2) d](/filings/0001079973-25-000555.md) | [(2.8)](/filings/0001553350-25-000046.md) | [(3.2)](/filings/0001079973-25-001297.md) | [(1.9)](/filings/0001079973-25-001713.md) | [(3.1) d](/filings/0001079973-26-000405.md) | [(1.8)](/filings/0001553350-26-000088.md) | [(1.5)](/filings/0001079973-26-001151.md) | [(1.1)](/filings/0001079973-25-001713.md) | [(3.4) d](/filings/0001079973-26-000405.md) | [(3.6)](/filings/0001553350-26-000088.md) | [0.0](/filings/0001079973-26-001151.md) |
| Interest expense | $m | [0.0](/filings/0001079973-23-001605.md) | [0.0 d](/filings/0001079973-24-000473.md) | [0.0](/filings/0001079973-24-000691.md) | [0.0](/filings/0001079973-25-001297.md) | [0.1](/filings/0001079973-25-001713.md) | [0.2 d](/filings/0001079973-26-000405.md) | [0.3](/filings/0001553350-26-000088.md) | [0.1](/filings/0001079973-26-001151.md) | [0.0](/filings/0001079973-25-001713.md) | [0.0 d](/filings/0001079973-26-000405.md) | not reported | [0.0](/filings/0001079973-26-001151.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [5.0](/filings/0001079973-26-001151.md) |
| Net income | $m | [(2.9)](/filings/0001079973-24-001587.md) | [(3.2) d](/filings/0001079973-25-000555.md) | [(2.8)](/filings/0001553350-25-000046.md) | [(3.2)](/filings/0001079973-25-001297.md) | [(1.4)](/filings/0001079973-25-001713.md) | [(3.4) d](/filings/0001079973-26-000405.md) | [(2.1)](/filings/0001553350-26-000088.md) | [(3.5)](/filings/0001079973-26-001151.md) | [(1.0)](/filings/0001079973-25-001713.md) | [(3.2) d](/filings/0001079973-26-000405.md) | [(3.5)](/filings/0001553350-26-000088.md) | [47.8](/filings/0001079973-26-001151.md) |
| Diluted EPS | $ per share | [(0.41)](/filings/0001079973-24-001587.md) | not reported | [(0.38)](/filings/0001553350-25-000046.md) | [(0.43)](/filings/0001079973-25-001297.md) | [(0.18)](/filings/0001079973-25-001713.md) | not reported | [(0.18)](/filings/0001553350-26-000088.md) | [(0.30)](/filings/0001079973-26-001151.md) | [(0.06)](/filings/0001079973-25-001713.md) | not reported | [(0.15)](/filings/0001553350-26-000088.md) | [1.35](/filings/0001079973-26-001151.md) |
| Basic EPS | $ per share | [(0.41)](/filings/0001079973-24-001587.md) | not reported | [(0.38)](/filings/0001553350-25-000046.md) | [(0.43)](/filings/0001079973-25-001297.md) | [(0.18)](/filings/0001079973-25-001713.md) | not reported | [(0.18)](/filings/0001553350-26-000088.md) | [(0.30)](/filings/0001079973-26-001151.md) | [(0.06)](/filings/0001079973-25-001713.md) | not reported | [(0.15)](/filings/0001553350-26-000088.md) | [1.58](/filings/0001079973-26-001151.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.3](/filings/0001079973-24-001587.md) | [2.4](/filings/0001079973-25-000555.md) | [3.0](/filings/0001079973-24-000691.md) | [0.5](/filings/0001079973-24-001218.md) | [0.6](/filings/0001079973-24-001587.md) | [6.3](/filings/0001079973-26-000405.md) | [3.8](/filings/0001553350-25-000046.md) | [1.5](/filings/0001079973-25-001297.md) | [33.2](/filings/0001079973-25-001713.md) | [15.5](/filings/0001079973-26-001151.md) | [33.0](/filings/0001553350-26-000088.md) | [112](/filings/0001079973-26-001151.md) |
| Current assets | $m | [6.8](/filings/0001079973-23-001605.md) | [6.3](/filings/0001079973-25-000555.md) | [6.4](/filings/0001079973-24-000691.md) | [3.4](/filings/0001079973-24-001218.md) | [4.4](/filings/0001079973-24-001587.md) | [8.1](/filings/0001079973-26-000405.md) | [7.5](/filings/0001553350-25-000046.md) | [4.8](/filings/0001079973-25-001297.md) | [37.2](/filings/0001079973-25-001713.md) | [21.9](/filings/0001079973-26-001151.md) | [41.4](/filings/0001553350-26-000088.md) | [130](/filings/0001079973-26-001151.md) |
| Total assets | $m | [13.4](/filings/0001079973-23-001605.md) | [12.8](/filings/0001079973-25-000555.md) | [12.7](/filings/0001079973-24-000691.md) | [21.2](/filings/0001079973-24-001218.md) | [22.0](/filings/0001079973-24-001587.md) | [35.0](/filings/0001079973-26-000405.md) | [34.1](/filings/0001553350-25-000046.md) | [31.1](/filings/0001079973-25-001297.md) | [69.8](/filings/0001079973-25-001713.md) | [63.4](/filings/0001079973-26-001151.md) | [123](/filings/0001553350-26-000088.md) | [241](/filings/0001079973-26-001151.md) |
| Current liabilities | $m | [3.4](/filings/0001079973-23-001605.md) | [3.2](/filings/0001079973-25-000555.md) | [3.1](/filings/0001079973-24-000691.md) | [5.8](/filings/0001079973-24-001218.md) | [6.0](/filings/0001079973-24-001587.md) | [16.1](/filings/0001079973-26-000405.md) | [14.0](/filings/0001553350-25-000046.md) | [13.1](/filings/0001079973-25-001297.md) | [9.7](/filings/0001079973-25-001713.md) | [9.6](/filings/0001079973-26-001151.md) | [12.2](/filings/0001553350-26-000088.md) | [15.3](/filings/0001079973-26-001151.md) |
| Total liabilities | $m | [7.7](/filings/0001079973-23-001605.md) | [7.5](/filings/0001079973-25-000555.md) | [7.2](/filings/0001079973-24-000691.md) | [18.4](/filings/0001079973-24-001218.md) | [19.5](/filings/0001079973-24-001587.md) | [32.7](/filings/0001079973-26-000405.md) | [28.9](/filings/0001553350-25-000046.md) | [26.4](/filings/0001079973-25-001297.md) | [20.3](/filings/0001079973-25-001713.md) | [14.9](/filings/0001079973-26-001151.md) | [16.0](/filings/0001553350-26-000088.md) | [33.9](/filings/0001079973-26-001151.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [5.7](/filings/0001079973-24-001587.md) | [5.4](/filings/0001079973-26-000405.md) | [5.5](/filings/0001079973-25-001713.md) | [2.9](/filings/0001079973-25-001713.md) | [2.5](/filings/0001079973-25-001713.md) | [2.3](/filings/0001079973-26-001151.md) | [5.2](/filings/0001079973-26-001151.md) | [4.7](/filings/0001079973-26-001151.md) | [49.5](/filings/0001079973-25-001713.md) | [48.6](/filings/0001079973-26-001151.md) | [107](/filings/0001079973-26-001151.md) | [207](/filings/0001079973-26-001151.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(3.7) d](/filings/0001079973-24-001587.md) | [(3.1) d](/filings/0001079973-25-000555.md) | [(2.0)](/filings/0001553350-25-000046.md) | [(1.9) d](/filings/0001079973-25-001297.md) | [(2.3) d](/filings/0001079973-25-001713.md) | [2.7 d](/filings/0001079973-26-000405.md) | [(4.7)](/filings/0001553350-26-000088.md) | [(3.2) d](/filings/0001079973-26-001151.md) | [(3.2) d](/filings/0001079973-25-001713.md) | [(2.7) d](/filings/0001079973-26-000405.md) | [(1.4)](/filings/0001553350-26-000088.md) | [12.7 d](/filings/0001079973-26-001151.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001079973-24-001587.md) | [0.3 d](/filings/0001079973-25-000555.md) | [0.0](/filings/0001553350-25-000046.md) | [0.9 d](/filings/0001079973-25-001297.md) | [0.7 d](/filings/0001079973-25-001713.md) | [0.3 d](/filings/0001079973-26-000405.md) | [0.6](/filings/0001553350-25-000046.md) | [0.8 d](/filings/0001079973-25-001297.md) | [6.4 d](/filings/0001079973-25-001713.md) | [15.8 d](/filings/0001079973-26-000405.md) | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [6.5](/filings/0001079973-23-001605.md) | [7.2](/filings/0001079973-24-000691.md) | [7.2](/filings/0001079973-24-001218.md) | [7.2](/filings/0001079973-24-001587.md) | [7.3](/filings/0001553350-25-000046.md) | [7.5](/filings/0001079973-25-001297.md) | [7.7](/filings/0001079973-25-001713.md) | [11.4](/filings/0001553350-26-000088.md) | [11.8](/filings/0001079973-26-001151.md) | [17.3](/filings/0001079973-25-001713.md) | [23.6](/filings/0001553350-26-000088.md) | [35.5](/filings/0001079973-26-001151.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 31,472,499 at 2026-08-18, from the cover of the [10-Q filed 2026-08-19](/filings/0001079973-26-001151.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.